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Association of cyclosporin A with acquired cystic kidney disease of the
native kidneys in renal transplant recipients. Acquired cystic kidney
disease (ACKD) is a common complication in patients treated with
long-term dialysis. Previous studies performed prior to the cyclosporin
A (CsA) era indicate that successful renal transplantation causes
regression of ACKD. Little has been published, however, on the
occurrence of ACKD in CsA-treated transplant recipients. We con-
ducted a prospective sonographic study in 33 renal transplant recipients
and 32 dialysis patients to evaluate the effect of CsA on ACKD in
transplant recipients. Transplant recipients had a lower prevalence
(39% vs. 56% in dialysis patients) and severity (smaller kidneys and
lower cyst grades) of ACKD when compared with dialysis patients.
Renal cell carcinoma was found in two dialysis patients. Using multiple
regression analysis, we found that the use of CsA was significantly
correlated with the presence of ACKD in transplant recipients (57% in
CsA-treated vs. 8% in non-CsA-treated patients). We conclude that
renal transplantation reduces the prevalence and severity of ACKD in
the native kidneys; however, among transplant patients, CsA adminis-
tration is associated with a greater prevalence of ACKD.
Acquired cystic kidney disease (ACKD) is a well character-
ized disease entity referring to bilateral, multiple cyst formation
in non-cystic failing kidneys [1]. Although Simon first described
the association of ACKD with end-stage renal disease (ESRD)
in 1847 [2], it was not until 1977 that the concept of ACKD was
formalized by Dunnill, Millard and Oliver [3]. ACKD, with its
potential complications of hemorrhage and neoplasia, is of
growing concern in the expanding population of patients under-
going dialysis [4, 5]. In 1983, Ishikawa et at [6] first demon-
strated regression of ACKD after successful renal transplanta-
tion. Other investigators also found that the prevalence of
ACKD was lower in transplant recipients when compared to
dialysis patients [7]. However, in a recent longitudinal prospec-
tive study of 61 renal transplant recipients, Ishikawa, Shikura
and Shinoda [8] reported that 33% of them had persistent or
progressive ACKD in the presence of good graft function. In
the 11 patients with progressive ACKD, one was found to have
renal cell carcinoma (RCC) eight years after renal transplanta-
tion. The presence of ACKD and RCC in transplant patients
with good graft function has been reported by other investiga-
tors [9—14] and was recently reviewed by Lien et al [14]. Most
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of these cases were middle-aged males with a prolonged dura-
tion of ESRD (5 to 15 years) and renal transplantation (2 to 15
years). It is clear that cystic transformation in the native
kidneys may continue after restoration of kidney function by
transplantation. Moreover, most of previous studies on ACKD
in transplant recipients were limited to patients receiving aza-
thioprine and prednisone. With the wide usage of cyclosporin A
(CsA), little has been published on the occurrence of ACKD in
CsA-treated transplant recipients. The data from the Cincinnati
Transplant Tumor Registry indicated that renal malignancy is
the fourth most common tumor in CsA-treated transplant
patients, ranked only after lymphomas, skin cancers, and
Kaposi's sarcoma [15]. To investigate the effect of CsA on
ACKD in renal transplant recipients, we performed a prospec-
tive sonographic study in both dialysis patients and renal
transplantation recipients.
Methods
In July 1991, we started obtaining renal sonographs of the
native kidneys of hemodialysis patients and renal transplant
recipients. Criteria for the study included patients' willingness
to undergo renal sonography and no history of underlying renal
cystic disease or bilateral nephrectomy. By October 1992, 72
hemodialysis patients and 78 transplant patients had been asked
to participate in this study. Among them, 32 hemodialysis
patients and 33 transplant patients agreed to undergo renal
sonography. Of the 32 hemodialysis patients, 15 were males and
17 were females. They had a mean age of 63 years (range, 35 to
87 years) and a mean duration of hemodialysis of five years
(range, ito 18 years). The 33 transplant recipients, 15 males and
18 females, had a mean age of 44 years (range, 14 to 70 years).
The mean duration of renal transplantation was seven years
(range, I to 20 years), and mean duration of dialysis prior to
transplantation was two years (range, 0 to 10 years). Twenty-
one patients received renal grafts from cadaveric donors and 12
from living-related donors. As for immunosuppression therapy,
21 were on a triple therapy of CsA, azathioprine and pred-
nisone, and 12 were on azathioprine and prednisone alone.
Seventeen out of the 21 cadaveric transplant recipients, and
four out of 12 living-related transplant recipients received CsA.
The selection of CsA treatment was mainly dependent on the
availability of CsA to patients. No conversion of immunosup-
pressive therapy was made after transplantation. The mean
plasma creatinine was 1.6 mgldl (range, 0.7 to 4.6 mg/dl). Only
one patient had a creatinine level greater than 3 mg/dl, four had
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Table 1. Comparison between transplant and dialysis patients
Transplant patients Dialysis patients
Patients number 33 32
ACKD % 13 (39%) 18 (56%)
Cyst grade
0 17 13
1+ 10 5
2+ 4 6
3+ 1 2
4+ 1 6
Kidney size cm
All patients 6.6 0.2 8.0 0.3a
ACKD (+) 7•7 8.6 03a,b
ACKD (—) 5.9 0.3 7.1 o.4
RCC % 0 (0%) 2 (6.3%)
Means SE or number of patients are shown.
ap < 0.05, dialysis patient vs. transplant recipientsbP < 0.05, ACKD (+) vs. ACKD (—)
a level between 2 and 3 mg/dl, and the rest of them below 2
mgldl.
Renal sonography was performed using a real-time Toshiba
ultrasonic scanner at the Radiology Department, University of
Arizona Health Sciences Center. Each kidney was assessed for
size, masses, and the number and location of separate and
distinct cystic structure using renal cross sections in longitudi-
nal and coronal planes. All present and available previous renal
sonographs were evaluated by KRH without reference to
details of the patient. Cysts were graded 0 to 4 according to the
number of cysts as described by Ishikawa et al [8]: grade 0 for
no cysts; 1+ for 1 to 2 cysts; 2+ for 3 to 5 cysts; 3+ for 6 to 10
cysts; and 4+ for more than 11 visible cysts. ACKD has been
diagnosed by various investigators in dialysis patients having
between one and five renal cysts. Ishikawa [161 has reported
that 94% of cysts in patients with ACKD are smaller than 6mm,
and suggested that patients with even a single cyst visible by
image study may be accompanied by 10 to 20 small undetected
cysts. On the other hand, it is not uncommon to find a single
cyst in normal individuals. Therefore, we decided to diagnose
ACKD as having two or more cysts, or having a newly
developed single cyst.
Potential risk factors, including age, gender, graft function,
duration of dialysis prior to transplantation, duration of renal
transplantation, immunosuppression therapy, type of donor,
and primary renal disease, were evaluated by chart review.
Statistical significance was determined by multiple linear re-
gression, chi-square test, or Student's t-test using the CRISP
software program (Jandel Scientific, San Rafael, California,
USA), with P < 0.05 being taken as significant.
Results
Table 1 shows the results of renal sonographs, including the
prevalence of ACKD and renal cell carcinoma, cyst grade and
kidney size. Hemodialysis patients had a higher prevalence of
ACKD (56% vs. 39%, P < 0.05) and a higher cyst grade (3+ or
greater, 25% vs. 6%, P < 0.05) when compared to transplant
patients. Three transplant recipients and one dialysis patient
had a new single cyst which was not seen in previous sono-
graphs. These four patients were diagnosed as having ACKD.
The kidney size was also significantly larger in dialysis patients,
with or without ACKD, compared to transplant patients. Two
hemodialysis patients were found to have RCC. One had distant
metastases at the time of diagnosis and died one month later.
The other had bilateral multiple renal masses, but did not
undergo bilateral nephrectomy because of poor cardiac func-
tion.
Nine transplant recipients and seven dialysis patients had
previous renal sonographs available. The mean duration be-
tween the previous and present studies was 16 (range, 12 to 23)
and 21 (range, 15 to 37) months, respectively, for transplant and
dialysis patients. Four transplant patients had no cysts, one had
a cyst grade of 2+ in both studies, three had a cyst grade
increase from 0 to 1+, and one from 1 + to 2+. All dialysis
patients with previous sonographs had progressive ACKD with
cyst grade advancing from 0 to 1 + in 3, 1 + to 2+ in one, 1+ to
4+ in one, and 2+ to 3+ in one, and cyst number increasing in
one who had a cyst grade of 4+ in both studies.
The results of risk factor analysis in transplant patients using
multiple regression are shown in Table 2. Age, gender, primary
renal disease, duration of dialysis prior to of renal transplanta-
tion, graft function, and donor type did not correlate with
ACKD (all P > 0.05). There was no correlation between
primary renal disease and ACKD as analyzed by chi-square test
(P > 0.05). The only variable significantly associated with
ACKD was CsA treatment (P = 0.03). Patients treated with
CsA, azathioprine, and prednisone had a significantly higher
prevalence of ACKD when compared with those on azathio-
prine and prednisone alone (57% vs. 8%).
Discussion
Our prospective sonographic study demonstrates that ACKD
is common in non-selected hemodialysis patients and renal
transplant recipients. The prevalence of ACKD in transplant
recipients was decreased when compared to hemodialysis pa-
tients. Also, transplant recipients with ACKD have lower cyst
grades, smaller native kidneys, and no occurrence of renal cell
carcinoma. In patients who had previous renal sonographs
available, all seven dialysis patients had a higher cyst grade or
cyst number on the present sonographs as compared to only
four of nine transplant patients. This limited retrospective study
suggests that the progression of ACKD may be more rapid in
dialysis patients than transplant patients. The lower prevalence
of ACKD in transplant patients is more dramatic in non-CsA-
treated patients where it was found in only 8% of the patients.
In CsA-treated transplant recipients, the prevalence of ACKD
is essentially the same as hemodialysis patients. From this, it is
clear that CsA is associated with a high prevalence of ACKD in
renal transplant recipients.
CsA is known to cause renal ischemia in renal grafts as well
as in native kidneys [17]. It has been hypothesized that ischemia
is one of the pathogenetic mechanisms of ACKD [16]. Cohen
and Elliot [18] reported four non-dialysis patients with unilat-
eral ACKD and ipsilateral renal artery occlusion (range of
plasma creatinine 1 to 10 mg/dl). Their observations strongly
suggest that ischemia per se is the underlying cause of ACKD.
Furthermore, ACKD has been reported in non-dialysis patients
with analgesic nephropathy [19] and nephrosclerosis [20]. Both
diseases are known to be associated with renal ischemia. We
speculate that CsA may cause ischemia in the native kidneys,
thereby playing a role in the pathogenesis of ACKD. This
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Table 2. Risk factor analysis by multiple regression in transplant patients
ACKD(-) ACKD(+) F P
Age years 45 3 (14—67) 41 5 (17—70) 0.6 >0.29
Male/female 11/9 4/9 1.7 0.20
Serum creatinine mg/dl 1.6 0.2 (0.8—4.6) 1.6 0.1 (0.7—2.7) 0.1 >0.29
Dialysis years 2.0 0.5 (0—10) 2.0 0.5 (0—8) 0.2 >0.29
Transplantation years 8.0 1.4 (1—20) 5.2 1.3 (2—20) 1.7 0.20
Primary renal disease — NS
Hypertension 2 1
Diabetes 3 2
CGN 7 5
Others 8 5
Type of donor 1.1 0.29
Living-related 10 2
Cadavenc 10 11
Immunosuppression 5.5 0.03
CsA(—) 11 1
C5A(+) 9 12
Means SE (range) or numbers of patients are shown. Abbreviation is CON, chronic glomerulonephritis.
a NS, non-significant, analyzed by chi-square test
hypothesis remains to be tested on a control population of
CsA-treated patients without any kidney diseases.
Our finding that more than one-half of CsA-treated renal
transplant recipients on CsA had renal cysts is alarming. ACKD
is viewed as a pre-malignant condition in dialysis patients. It is
estimated that 20% of dialysis patients with ACKD have renal
tumors which have a metastatic rate of 5% [21]. Two recent
longitudinal studies using contrast-enhanced CT scan demon-
strated that ACKD is a progressive disease in dialysis patients,
which was evidenced by an increase in kidney size, cyst grades
and occurrence of renal malignancy over several years of
dialysis [22, 23]. It is recommended by some investigators, but
not all, to screen ESRD patients who have been on dialysis for
more than three years with an annual renal imaging study.
Whether the native kidneys of renal transplant recipients should
be screened for ACKD has yet to be addressed. ACKD and
associated RCC has been reported in renal transplant recipients
with good renal function. Most of them are middle-aged men
with a prolonged history of ESRD and renal transplantation.
The immunosuppressive agents in those patients were azathio-
prine and prednisone [14]. As for CsA-treated transplant pa-
tients, renal malignancy is ranked as the fourth most common
malignancy. It was speculated that these renal tumors may be
part of the syndrome of ACKD that complicates ESRD [15]. At
present, it is not clear whether the ACKD in CsA-treated
patients would progress along a similar course as in dialysis
patients. A prospective longitudinal study on CsA-treated pa-
tients is needed to understand the natural history of ACKD in
these patients. If, indeed, those patients with ACKD are also at
risk of developing renal tumors, it would be necessary to screen
the native kidneys of CsA-treated transplant patients periodi-
cally.
In conclusion, we have confirmed that renal transplantation
reduces the frequency and seventy of ACKD in patients with
ESRD; however, it does not eliminate ACKD even in patients
with good renal function. Administration of CsA is the major
risk factor for the development or persistence of ACKD in
transplant patients, a finding suggesting that renal ischemia may
be involved in cyst formation in failing kidneys. A prospective
longitudinal study of the native kidneys in CsA-treated renal
transplant recipients is needed to determine whether periodic
screening of these patients for ACKD and renal tumors is
indicated.
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